H.C. Wainwright reiterates Buy on Phathom stock, $26 target
H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.
How this was made
The 30-second read
Why it matters
The earnings beat and higher price target may attract momentum traders, but execution risk remains.
Market read
The news provides fresh earnings data and an upgraded target for PHAT, offering a potential short‑term trade idea.
What to watch
Potential regulatory hurdles for VOQUEZNA and the modest revenue miss could temper upside.
Background
Phathom Pharmaceuticals (PHAT) is a micro‑cap biotech focused on GI disorders, recently reporting Q3 2026 results and receiving an analyst upgrade.
Ticker impact
H.C. Wainwright reiterated a Buy rating and raised the price target to $26 after Phathom's Q3 2026 earnings beat expectations on EPS and highlighted commercial momentum.
likely upward pressure as the market prices in the higher target and earnings beat.
The fresh earnings numbers and upgraded target are new information that can drive buying interest.
Market effects
Positive signal for the GI‑focused biotech sector as a peer shows revenue growth and profitability path.
Limited to US small‑cap biotech investors.
Minimal; primarily affects niche biotech investors.
Counterpoint
The stock remains far below the $26 target and may face execution risk on its pipeline.
Key entities
- companyPhathom Pharmaceuticals
NASDAQ‑listed biotech developing VOQUEZNA for GERD/NERD.
- analystH.C. Wainwright
Equity research firm that reiterated a Buy rating and raised the target.



